Genmab ditches drug candidate
The biotech firm genmab shelves cancer project which US J.P. Morgen predicted would have sales potential at USD 2bn per year.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
The Danish biotech firm Genmab has lost a potential blockbuster drug. Genmab has decided to ditch the drug candidate enapotamab vedotin for treating cancer, which the firm announces in a statement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
